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and hepatobiliary cholesterol efﬂux, may simultaneously inﬂuence plasma and biliary cholesterol levels, and hence
risk of myocardial infarction (MI) and gallstone disease in opposite directions.Background High plasma levels of low-density lipoprotein (LDL) cholesterol are a causal risk factor for MI, whereas high levels
of biliary cholesterol promote gallstone formation.Methods A total of 60,239 subjects from Copenhagen were included, including 5,647 with MI and 3,174 with symptomatic
gallstone disease. Subjects were genotyped for 6 common, nonsynonymous and functional variants in ABCG5/8,
and a combined weighted genotype score was calculated.Results Combined, weighted genotype scores were associated with stepwise decreases in LDL cholesterol of up to 5.9% (0.20
mmol/l) for individuals with a score 8.0 (prevalence ¼ 11%) versus <2.0 (prevalence ¼ 9%; p for trend across 5
groups ¼ 2  10E-35). The cumulative incidences of MI and gallstone disease as a function of age and increasing
genotype score were decreased and increased (log-rank ps for trend: 6  10E-4 and 9  10E-45), respectively. The
multifactorially adjusted odds ratios were 0.83 (95% conﬁdence interval: 0.73 to 0.94) forMI and 2.85 (95% conﬁdence
interval: 2.39 to 3.39) for symptomatic gallstone disease for individuals with a genotype score 8.0 versus <2.0.Conclusions Genetic variation in ABCG5/8, which associates with decreased levels of plasma LDL cholesterol protects
against MI, but increases the risk of symptomatic gallstone disease. These results suggest that MI and gallstones,
2 seemingly unrelated diseases, are intrinsically linked via the function of the ABCG5/8 cholesterol
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the most common form of gallstones in the West (1,2).
The adenosine triphosphate–binding cassette transporter
G5/8 (ABCG5/8) efﬂuxes sterols including cholesterol from
enterocytes and hepatocytes into the intestine and bile, respec-
tively, and may therefore simultaneously lower plasma choles-
terol levels and increase biliary cholesterol excretion (Fig. 1) (3).See page 2129This is clinically important, because drugs such as statins,
ezetimibe, and ﬁbrates, which all lower plasma cholesterol
and hence protect against ischemic heart disease, may have
opposite effects on biliary cholesterol levels, depending on
whether they up- or down-regulate biliary cholesterol
excretion via ABCG5/8. As a consequence, these drugs
either protect against (statins) or may increase (ezetimibe
and ﬁbrates) the risk of gallstone disease (4,5).
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2122In the present study, we hy-
pothesized that genetic variation
inABCG5/8, the 2 genes that each
encode half of the ABCG5/8
cholesterol transporter, may in-
ﬂuence risk of MI and gallstone
disease in opposite directions.
We genotyped all common
nonsynonymous variants (minor
allele frequency>5%) inABCG5/
8 (ABCG8D19H,Y54C, T400K,A632V; ABCG5 Q604E) and a functional intronic variant
(ABCG8 IVS3þ981) in 2 prospective studies of the Danish
general population, CGPS (Copenhagen General Population
Study) and CCHS (Copenhagen City Heart Study), and in a
case-control study, CIHDS (Copenhagen Ischemic Heart
Disease Study), totaling 60,239 participants, including 5,647
with MI and 3,174 with symptomatic gallstone disease.
We subsequently tested whether ABCG5 and ABCG8 geno-
types, individually or combined, were associated with plasma
levels of LDL cholesterol and other lipids and lipoproteins,
and with risk of MI and symptomatic gallstone disease.
Methods
Studies were approved by institutional review boards and
Danish ethical committees, and were conducted according
to the Declaration of Helsinki. Written informed consent
was obtained from participants. All participants were white
and of Danish descent, as determined by the National
Danish Person Registration System. There was no overlap of
individuals between the studies.
Participants. We included participants in 2 studies of the
Danish general population, the CGPS and CCHS studies,
and a case-control study, the CIHDS study (6–9). To
achieve maximal statistical power, these 3 studies were
combined, yielding a total of 60,239 participants, including
5,647 with MI and 3,174 with symptomatic gallstone dis-
ease. For a detailed description of the cohorts, see the
Online Appendix.
Diagnoses, genotyping, laboratory analyses, and other
covariates. See the Online Appendix for information on di-
agnoses, genotyping, laboratory analyses, and other covariates.
Statistical analyses. Datawere analyzedusingSTATA/SE12
(StataCorp, College Station, Texas). Chi-square tests eval
uated Hardy-Weinberg equilibrium. Mann-Whitney U test
or Pearson chi-square test were used in 2-group compari-
sons. Tests for trend as a function of genotypes, individually
or combined, were by Cuzick’s extension of aWilcoxon rank
sum test with genotypes coded 1, 2, 3, and so forth. Kruskal-
Wallis analysis of variance or Pearson chi-square test evaluated
the association of genotypes with potential confounders.
From the 5 genotypes that were individually associated
with reductions in LDL cholesterol levels, we generated
combined, weighted genotype scores based on the percent-
age reductions in LDL cholesterol compared to thereference genotype: ABCG8 D19H, DD ¼ 0, DH ¼ 2.7,
HH ¼ 5.8; IVS3þ981 T>C, CC ¼ 0, TC ¼ 2.5, TT ¼
4.5; Y54C, YY ¼ 0, YC ¼ 0.2, CC ¼ 1.1; T400K, TT ¼ 0,
TK ¼ 0.9, KK ¼ 2.9; A632V, VV ¼ 0, AV ¼ 0.9,
AA ¼ 1.1. For each participant, a weighted genotype score was
then calculated by summation of scores across the 5 genetic
variants (range 0.0 to 14.3). The weighted genotype scores
were divided into 5 groups: <2.0 (reference), 2.0 to 3.9, 4.0
to 5.9, 6.0 to 7.9, and 8.0 (Online Table 1). In sensitivity
analyses, we grouped the genotype scores by approximate
tertiles, quartiles, or quintiles. A genotype score was also
generated for variants in the LDLR (W23X, W66G,
W556S), APOB (R3500W, rs5742904), and PCSK9
(R46L, rs11591147) (6), known to associate with plasma
levels of LDL cholesterol, but not with levels of plant
sterols (10). In analyses stratiﬁed on ABCG8 D19H, a
weighted genotype score without D19H was constructed
(i.e., including IVS3þ981, Y54C, T400K, and A632V).
Kaplan-Meier curves and log-rank tests for trend evalu-
ated the cumulative incidences of MI and gallstone disease
as a function of age and weighted genotype scores. Logistic
regression analyses, adjusted for age and sex, or multifacto-
rially for age, sex, body mass index, hypertension, diabetes
mellitus, physical activity, smoking, alcohol consumption,
hormone replacement therapy (women only), triglycerides,
and high-density lipoprotein cholesterol, or for all of the
previous including lipid lowering therapy, and in addition
for LDL cholesterol corrected for lipid-lowering therapy (6),
estimated odds ratios (ORs) for MI in the CGPS, CCHS,
and CIHDS studies combined, or symptomatic gallstone
disease in the CGPS and CCHS studies combined. Hazard
ratios for incident MI/gallstone disease as a function of
prevalent gallstone disease/MI were estimated by Cox
regression. In multifactorially adjusted analyses, missing data
on covariates (<3%) were imputed based on age and sex. We
used instrumental variable analysis (6–8), to compare the
effect on risk of MI of a 1 mmol/l decrease in LDL
cholesterol due to either variants in ABCG5/8 or variants in
LDLR, APOB, and PCSK9 (see the Online Appendix for
details). To test whether the associations were independent
of ABCG8 D19H, a known gain-of-function variant
strongly associated with increased risk of gallstones, analyses
were also stratiﬁed on D19H genotype (9,11,12).Results
Clinical characteristics. Baseline characteristics of in-
dividuals with MI or symptomatic gallstone disease are
shown in Table 1. Conventional risk factors for MI or
gallstone disease were equally distributed among genotypes,
although use of lipid-lowering therapy tended to be less
frequent among carriers of LDL cholesterol decreasing ge-
notypes versus noncarriers (Online Table 2). Genotype
frequencies did not deviate from those predicted by the
Hardy-Weinberg equilibrium. ABCG5 R50C and ABCG8
D19H were in almost complete linkage disequilibrium in
Figure 1 Schematic of the Biological Function of ABCG5/8
Adenosine triphosphate–binding cassette transporter G5/8 (ABCG5/8) efﬂuxes sterols including cholesterol from enterocytes and hepatocytes into the intestine and bile,
respectively, and may therefore simultaneously lower plasma cholesterol levels and increase biliary cholesterol excretion. Reduced plasma levels of cholesterol would be
expected to reduce the risk of atherosclerosis and in turn the risk of myocardial infarction, whereas elevated levels of biliary cholesterol promote the formation of gallstones.
NPC1L1, the target of the lipid-lowering drug ezetimibe, is included for comparison. NPC1L1 mediates the uptake of sterols including cholesterol from the intestine and bile into
enterocytes and hepatocytes.
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2123the CCHS (D’ ¼ 0.98; r2 ¼ 0.94), as previously described
(11), and therefore only D19H was genotyped in the CGPS
and the CIHDS studies (Online Fig. 1). For additional data
on the epidemiological associations between gallstone dis-
ease and MI, or between LDL cholesterol and gallstones,
see the Online Appendix.
Plasma lipid and lipoprotein levels. Nonfasting plasma
levels of lipids and lipoproteins as a function of ABCG8/5
genotypes, individually and combined, are shown in
Figure 2. For all genotypes except ABCG5 Q604E, there
were stepwise decreases in total and LDL cholesterol levels as
a function of genotypes from 0.8% (0.04 mmol/l) to 4.1%Table 1 Baseline Characteristics of Participants
No Event
Myocardial
Infarction
Symptomatic
Gallstone
Disease
Number of participants 51,654 5,647 3,174
Women, % 28,537 (55) 1,703 (30)* 2,269 (71)*
Age, years 56 (46–66) 66 (58–74)* 62 (52–70)*
Body mass index, kg/m2 25 (23–28) 27 (24–30)* 27 (24–30)*
Hypertension, % 29,132 (56) 2,993 (53) 2,029 (64)*
Diabetes mellitus, % 1,689 (3) 618 (11)* 184 (6)*
Physical activity, % 24,028 (47) 937 (35)*y 1,109 (35)*
Smoking, % 13,217 (26) 1,963 (38)* 927 (29)*
Alcohol consumption, % 9,227 (18) 419 (15)*y 383 (12)*
Hormone replacement
therapy, %z
3,775 (13) 143 (15)y 427 (19)*
Lipid-lowering therapy, % 3,485 (7) 2,014 (36)* 318 (10)*
Values are n (%) or median (interquartile range). *p < 0.001 versus individuals with no event.
yInformation on physical activity, alcohol consumption, and hormone replacement therapy was only
available in w2,700 participants with myocardial infarction. zIn women only.(0.24 mmol/l) for total cholesterol and 1.1% (0.04 mmol/l) to
5.8% (0.19 mmol/l) for LDL cholesterol, in homozygotes
versus noncarriers (p for trend: 0.08 to 1  10–28). When
combining the 5 LDL-associated genotypes into weighted
genotype scores, there were stepwise decreases in total and
LDL cholesterol of up to 3.8% (0.22 mmol/l) and 5.9% (0.20
mmol/l), respectively, for individuals with a genotype score
of 8.0 versus <2.0 (p for trend: 1  10–32 and 2  10–35)
(Fig. 2). The relationship between genotype score and LDL
cholesterol was approximately linear: A 1-U increase in ge-
notype score was associated with on average 0.025 mmol/l
lower LDL cholesterol. None of the variants, individually or
combined, were associated with plasma levels of high-density
lipoprotein cholesterol or triglycerides (Fig. 2).
Risk of myocardial infarction and symptomatic gallstone
disease. In total 5,647 individuals had MI and 3,174 in-
dividuals had symptomatic gallstone disease. In individuals
with a genotype score <4.0 through 4.0 to 7.9 to 8.0, there
was a stepwise decrease in the cumulative incidence of MI
(Fig. 3, upper panel) (log-rank trend p ¼ 6  10–4), and a
corresponding stepwise increase in risk of gallstone disease
(Fig. 3, lower panel) (p ¼ 9  10–45).
The relationships between genotype score and risk of MI
and gallstone disease were approximately linear, with much
stronger effects on symptomatic gallstone disease than onMI.
The multifactorially adjusted OR for MI was 0.83 (95%
conﬁdence interval [CI]: 0.73 to 0.94) for individuals with
a genotype score of 8.0 versus <2.0 (p for trend across 5
groups ¼ 2  10–4), and the corresponding OR for symp-
tomatic gallstone disease was 2.85 (95%CI: 2.39 to 3.39; p for
trend ¼ 1  10–45) (Fig. 4). Further adjustments for lipid-
Figure 2 Lipid and Lipoprotein Levels as a Function of ABCG5/8 Genotypes, Individually and Combined
The genotype score was constructed by summation of weighted low-density lipoprotein (LDL) cholesterol lowering genotypes of adenosine triphosphate–binding cassette
transporter G8 (ABCG8) D19H, IVS3þ981, T400K, Y54C, and A632V. The p values are for trend tests by Cuzick’s extension of a Wilcoxon rank sum test.
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2124lowering therapy alone, or for LDL cholesterol corrected for
lipid-lowering therapy, marginally or partially attenuated the
associations with MI, but not with gallstone disease (Online
Fig. 2). For the individual genotypes, ORs for MI ranged
from 0.83 (95% CI: 0.76 to 0.92) for IVS3þ981 TT to 1.07
(95% CI: 0.91 to 1.25) for T400K KK versus noncarriers,
while ORs for gallstone disease ranged from 3.82 (95% CI:
2.66 to 5.49) forD19HHH to 1.11 (95%CI: 0.99 to 1.23) for
Y54C CC versus noncarriers (Online Fig. 3).
In sensitivity analyses, we repeated the analyses using other
methods of grouping the genotype score (approximate tertiles,
quartiles, or quintiles). This did not change the results sub-
stantially for risk of MI or gallstone disease (Online Fig. 4).
Genetically reduced LDL cholesterol and risk of
myocardial infarction. In instrumental variable analysis,
the risk ratios for MI for a similar 1 mmol/l reduction in
LDL cholesterol for variants in ABCG5/8 (which associate
with LDL cholesterol and plant sterols [13]) and for variants
in LDLR, APOB, and PCSK9 (which associate with LDL
cholesterol, and not with plant sterols) were nearly identical:0.42 (95% CI: 0.23 to 0.78) and 0.43 (95% CI: 0.25 to
0.70), respectively (p for comparison ¼ 0.95) (Fig. 5).
Stratiﬁcation on ABCG8 D19H genotype. As previously
shown in this cohort (9), the H-allele of D19H was a strong
risk factor for symptomatic gallstone disease, with stepwise
increased ORs of up to 3.82 (95% CI: 2.66 to 5.49) for
HHversusDD-homozygotes (p for trend: 7 10–56) (Online
Fig. 3). Therefore, to assess whether the other ABCG5/8
variants were independently associated with LDL cholesterol,
and with risk of MI and/or symptomatic gallstones, we tested
this on a D19H DD wild-type background (Fig. 6).
Among ABCG8D19HDD-homozygotes (n¼ 52,769, or
88% of the population), a genotype score constructed from
the remaining LDL-lowering variants was associated with
stepwise decreases in LDL cholesterol of up to 4.1% (0.14
mmol/l) for individuals with a genotype score of 6.0
versus <2.0 (p for trend: 5  10–22) (Fig. 6). The corre-
sponding multifactorially adjusted ORs for MI and symp-
tomatic gallstone disease were 0.88 (95% CI: 0.80 to 0.98),
and 1.74 (95% CI: 1.48 to 2.05), respectively (p for trend
Figure 3
Cumulative Incidence of Myocardial Infarction and
Symptomatic Gallstone Disease as a Function of
Age and ABCG5/8 Genotype Score
The genotype score was constructed by summation of weighted low-density
lipoprotein cholesterol lowering genotypes of adenosine triphosphate–binding
cassette transporter G8 (ABCG8) D19H, IVS3þ981, T400K, Y54C, and A632V.
The p values are by log-rank trend test.
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2125across 4 groups¼ 0.003 and 310–15) (Fig. 6). Results for the
individual genotypes were generally consistent with those
presented previously for the genotype score (Online Fig. 5).
The power to detect associations was naturally low in the
smaller subgroup of D19H DH-heterozygotes and HH-
homozygotes combined (n ¼ 7,470, or 12% of the popula-
tion) (Online Fig. 6).Discussion
The main ﬁnding of this study is that genetic variation in
ABCG5/8 associated with decreased levels of plasma LDL
cholesterol protects against MI, but increases the risk of
symptomatic gallstone disease. These results suggest that MI
and gallstones, 2 seemingly unrelated diseases, are intrinsi-
cally linked via the function of the ABCG5/8 cholesterol/
sterol transporter.
This is the ﬁrst study to simultaneously assess plasma lipid
levels, risk of MI, and risk of symptomatic gallstone disease
as a function of genetic variation in ABCG5/8, and the ﬁrst
study to use combined genotype scores. Previous studies
have reported associations for individual genetic variants
with plasma lipid levels, risk of MI, or risk of gallstone
disease viewed in isolation: ﬁrst, common genetic variation
in ABCG5/8 consistently associates with plasma levels of
LDL cholesterol (14). Second, homozygosity for complete
loss-of-function variants in ABCG5/8 causes sitosterolemia,
a rare disease characterized by elevated levels of plasma plant
sterols, moderately elevated total cholesterol, and increased
risk of premature MI (15). Third, recent studies have
identiﬁed modest associations between common variants
in ABCG5/8 and risk of ischemic cardiovascular disease
(10,16,17). Fourth, it is ﬁrmly established that ABCG8
D19H constitutes a risk factor for gallstone disease (12).
The mechanistic interpretation of the data presented here is
straightforward. Gain-of-function genetic variation in ABCG5/
8 increases intestinal and hepatobiliary sterol including choles-
terol efﬂux, reduces levels of plasma LDL cholesterol and
consequently protects against MI, but at the cost of increasing
the risk of gallstone disease due to elevated levels of biliary
cholesterol; the latter was naturally not measured in individuals
in the present large studies. Conversely, genetic variation asso-
ciated with reduced activity of ABCG5/8 increases the risk of
MIdue toelevatedplasmaLDLcholesterol, butprotects against
gallstones due to reduced biliary cholesterol. This interpretation
is in agreement with results from animal models, in which
overexpression of ABCG5/8 reduces plasma sterol including
cholesterol levels and protects against atherosclerosis, but in-
creases biliary cholesterol levels (18,19), whereas knockout of
ABCG5/8 increases plasma cholesterol levels, but decreases
biliary cholesterol levels (20). Moreover, we observed that vari-
ants in ABCG5/8, which were associated with plasma levels of
LDL cholesterol, had amuch stronger effect on risk of gallstone
disease than onMI. This ﬁts well with the fact that ABCG5/8
efﬂuxes sterols directly into bile (and the intestinal lumen),
whereas the effect on plasma LDL is a secondary phenomenon.
The link between plasma and biliary cholesterol is clini-
cally important, because LDL cholesterol lowering drugs
such as statins, ezetimibe, and ﬁbrates may have opposite
effects on biliary cholesterol levels, depending on whether
they up- or down-regulate biliary cholesterol excretion via
ABCG5/8. As a consequence, these drugs either protect
against (statins) or may increase (ezetimibe and ﬁbrates) the
risk of gallstone disease (4,5).
Figure 4 Risk of Myocardial Infarction and Symptomatic Gallstone Disease as a Function of ABCG5/8 Genotype Score
The genotype score was constructed by summation of weighted low-density lipoprotein (LDL) cholesterol lowering genotypes of adenosine triphosphate–binding cassette
transporter G8 (ABCG8) D19H, IVS3þ981, T400K, Y54C, and A632V. The p values are for trend tests by Cuzick’s extension of a Wilcoxon rank sum test, or for trend
tests of odds ratios (ORs). CI ¼ conﬁdence interval.
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2126Another clinically relevant question is whether gallstone
disease per se associates with a decreased risk of MI. Previous
studies have reported inconsistent epidemiological associa-
tions between MI and gallstone disease (21,22). In our
study, prevalent gallstone disease did not inﬂuence the risk
of future MI.
Myocardial infarction. LDL cholesterol is a well-known
causal risk factor for MI and other ischemic cardiovascular
endpoints. Concordantly, we observed that genetic variation
in ABCG5/8 that associated with a 5.9% reduction in LDL
cholesterol was also associated with an odds ratio for MI of
0.83 (i.e., a 17% lower risk).
The common genetic variants in ABCG5/8 that associate
with reduced plasma LDL cholesterol are known to also
associate with reduced levels of plasma plant sterols (13). It has
been suggested that moderately elevated plasma levels of plant
sterols could be atherogenic (23). Therefore, an alternative
explanation to the reduced risk of MI observed for carriers of
LDL cholesterol lowering variants in our study could be that
these individuals also had genetically determined lower plasma
levels of plant sterols. To elucidate this, we compared the effect
of the LDL lowering ABCG5/8-variants to that of LDL-
lowering variants in LDLR, APOB, and PCSK9, which doFigure 5
Risk of Myocardial Infarction for a 1 mmol/l Decrease in L
LDLR, APOB, and PCSK9 or ABCG5/8
Risk ratios were estimated by instrumental variable analysis. The p values indicate signi
genotype scores of variants in LDLR/APOB/PCSK9 or adenosine triphosphate–binding ca
(>10 indicates sufﬁcient strength). R2 ¼ percent contribution of genetic instrument to thnot associate with plant sterols. The risk of MI for a similar
reduction in LDL cholesterol for ABCG5/8 variants was
virtually identical to that seen for variants in LDLR, APOB,
and PCSK9, suggesting that the ABCG5/8-mediated protec-
tion against MI observed in our study was mediated by lower
levels of LDL cholesterol, and not by lower levels of plant
sterols. In agreement with this, 2 recent studies suggested that
elevated plant sterol levels, at least within the normal range, are
not a causal risk factor for the development of atherosclerosis.
First, a large systematic review andmeta-analysis didnot report
an association between serum concentrations of plant sterols
and risk of cardiovascular disease (24). Second, heterozygotes
for a rare loss-of-function variant in ABCG8 had 36% elevated
levels of plasma plant sterols, no change in LDL cholesterol,
and slightly decreased carotid intima-media wall thickness
(a proxy for atherosclerosis) (25). Taken together, it therefore
seems unlikely that reduced plant sterols played a major role in
the protection against MI seen in carriers of LDL cholesterol
lowering ABCG5/8 variants in our study.
Common genetic variants in ABCG5/8 may be useful
to include in genetic scores for predicting risk of MI and
other cardiovascular endpoints. For instance, a common
intronic ABCG8 variant was recently used together withDL Cholesterol Due to Genetic Variation in
ﬁcance of risk ratio. The p comparison value reports between the estimate from
ssette transporter G5/8 (ABCG5/8). F ¼ strength of the genetic instrument
e variation in low-density lipoprotein (LDL) cholesterol. CI ¼ conﬁdence interval.
Figure 6
Risk of Myocardial Infarction and Symptomatic Gallstone Disease as a Function of ABCG5/8 Genotype Score
on a D19H DD Background
The genotype score was constructed by summation of weighted low-density lipoprotein (LDL) cholesterol lowering alleles of adenosine triphosphate–binding cassette transporter
G8 (ABCG8) IVS3þ981, T400K, Y54C, and A632V. The p values are for trend tests by Cuzick’s extension of a Wilcoxon rank sum test, or for trend tests of odds ratios (ORs).
CI ¼ conﬁdence interval.
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212711 other common LDL-related variants to construct a gene
score (26). This gene score was strongly associated with
increased LDL cholesterol, and consequently also with an
increase in risk of familial hypercholesterolemia, demon-
strating the potential clinical use of gene scores based on
multiple common variants in LDL-related genes, including
ABCG5/8 (26).
Symptomatic gallstone disease. The H-allele of ABCG8
D19H is a strong risk factor for gallstone disease, comparable
inmagnitude towell-known risk factors such as female sex and
obesity (7,9,12). The H-allele of D19H increases the trans-
port activity of ABCG5/8 approximately 3-fold in vitro,
indicating that the variant likely confers a gain of function that
increases cholesterol efﬂux from the liver into the gallbladder
(11). Cholesterol supersaturation in the bile is a key event in
the formation of cholesterol gallstones (2). Apart fromD19H,
other genetic variants in ABCG5/8 have not been consistently
associated with risk of gallstones. Although 3 smaller studies
(287 gallstone cases) have reported associations for ABCG5
Q604E and ABCG8T400K with risk of gallstone disease, the
large genome-wide association study (n ¼ 2,280 cases) that
initially identiﬁed ABCG8 D19H did not report other risk
variants in ABCG5/8 (27–30). However, re-evaluating the
thorough ﬁne-mapping of variants in the ABCG5/8-region
performed in this genome-wide association study revealed
that ABCG8 IVSþ981 and T400K, as well as ABCG5
Q604E, were indeed associated with gallstone disease, but
that the associations did not reach the stringent requirements
for statistical signiﬁcance and/or replication (30). We found
that ABCG8 IVSþ981 and T400K, as well as ABCG5
Q604E,were individually associated with risk of symptomatic
gallstone disease independent of D19H genotype. In other
words, these data, and the results from the studies mentioned
previously (27–30), suggest that D19H is not the only litho-
genic variant at the ABCG5/8 locus.
By which mechanisms might the non-D19H variants pro-
mote the formation of gallstones? For ABCG8 IVS3þ981
and T400K, the gallstone risk alleles were also associated
with decreased levels of plasma LDL cholesterol. Thisresembles the association seen for D19H, suggesting that
gain-of-function effects similar to the H-allele of D19H
might underlie the associations for IVS3þ981 and T400K.
Indeed, the gallstone-associated T-allele of IVS3þ981 has
previously been associated with an increased expression
of ABCG8 mRNA (i.e., a gain-of-function effect) (10).
ABCG5 Q604E was associated with an increased risk of
symptomatic gallstone disease in heterozygotes, but in
contrast to the ABCG8 alleles that increased the risk of
gallstones in the present study, Q604E did not associate
with low LDL cholesterol. The reason for this discrepancy
remains to be elucidated.
Study limitations and strengths. There are naturally po-
tential limitations as well as strengths to our study. A strength
of our genetic study is that we studied only white individuals
from an ethnically homogeneous population. Although our
results may therefore not necessarily apply to other ethnicities,
we are not aware of data to suggest that our results should
not be applicable to all humans. We deﬁned symptomatic
gallstone disease by International Classiﬁcation of Diseases-
codes for cholelithiasis or cholecystitis diagnosed in hospi-
tal. This deﬁnition most likely captured symptomatic
gallstones veriﬁed by ultrasound. Accordingly, approximately
68% of participants with “symptomatic gallstone disease”
underwent cholecystectomy in this cohort (9). However, we
cannot rule out that a small part of gallstone cases had
asymptomatic gallstones diagnosed incidentally. Because
diagnoses of MI were extensively validated by reviewing
medical records, and because MI is a hard clinical endpoint
with well-deﬁned diagnostic criteria, major misclassiﬁcation
of the MI endpoint was very unlikely. We hypothesized that
the LDL-lowering ABCG5/8-variants conferred a gain of
function. However, this has only been shown experimentally
for the H-allele of D19H (11). Plant sterols were not
measured in our cohorts. As discussed previously, we pro-
vided indirect evidence that plant sterols were not likely to
have inﬂuenced the risk of MI. However, other cohorts with
measurements of both LDL cholesterol and plant sterols
may be better suited to directly assess the LDL cholesterol
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2128versus plant sterol effect on risk of MI (10,17). Finally,
strengths of our study also include the large sample sizes, the
large number of endpoints mainly from individuals in the
general population, and no losses to follow-up.
Conclusions
Common genetic variation in ABCG5/8 that associates with
decreased levels of plasma LDL cholesterol protects against
MI, but increases the risk of symptomatic gallstone disease
in the general population.
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